Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1641 to 1650 of 2605 total matches.

Insulins for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
Insulins for Type 2 Diabetes The goal of drug therapy for type 2 diabetes is to achieve ...
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin is the preferred first-line treatment, but most patients with type 2 diabetes eventually require multidrug therapy and/or insulin to achieve glycemic control.
Med Lett Drugs Ther. 2019 May 6;61(1571):65-8 |  Show IntroductionHide Introduction

Fluticasone Furoate (Arnuity Ellipta) for Asthma

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015  (Issue 1469)
The Medical Letter® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 (Issue ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Med Lett Drugs Ther. 2015 May 25;57(1469):76-9 |  Show IntroductionHide Introduction

PARP Inhibitors for Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017  (Issue 1535)
with placebo (19.1 vs 5.5 months).7 Drug Interactions – Olaparib is metabolized primarily by CYP3A4/5 ...
Three oral poly(ADP-ribose) polymerase (PARP) inhibitors have been approved by the FDA for treatment of advanced, recurrent ovarian cancer. Olaparib (Lynparza – AstraZeneca), niraparib (Zejula – Tesaro), and rucaparib (Rubraca – Clovis) are each approved for somewhat different indications and for patients with different biomarkers (see Table 2).
Med Lett Drugs Ther. 2017 Dec 4;59(1535):200-2 |  Show IntroductionHide Introduction

Foods Interacting With MAO Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 1989  (Issue 785)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Many fermented foods contain tyramine as a byproduct formed by the bacterial breakdown of the amino acid tyrosine; it can also be formed by para-hydroxylation of phenylethylamine or dehydroxylation of DOPA and dopamine. Tyramine and some other amines found in food can cause hypertensive reactions in patients taking monoamine oxidase (MAO)inhibitors.
Med Lett Drugs Ther. 1989 Feb 10;31(785):11-2 |  Show IntroductionHide Introduction

Beta-blockers For Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2000  (Issue 1081)
The Medical Letter  On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 Main ...
Standard treatment for patients with heart failure has included a diuretic, digitalis and an ACE inhibitor. In recent years carvedilol, a nonselective beta-blocker with alpha-1 blocking activity, and the beta-selective blockers bisoprolol and metroprolol have also been used for this indication.
Med Lett Drugs Ther. 2000 Jun 26;42(1081):54-5 |  Show IntroductionHide Introduction

Esomeprazole (Nexium)

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001  (Issue 1103)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Esomeprazole magnesium (Nexium - AstraZeneca), the S-isomer of omeprazole (Prilosec), is the fifth benzimidazole proton pump inhibitor to become available in the United States. Omeprazole, which was the first, is going off patent this year.
Med Lett Drugs Ther. 2001 Apr 30;43(1103):36-7 |  Show IntroductionHide Introduction

Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002  (Issue 1129)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Valdecoxib (Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx), was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.
Med Lett Drugs Ther. 2002 Apr 29;44(1129):39-41 |  Show IntroductionHide Introduction

Oxaliplatin (Eloxatin) for Advanced Colon Cancer

   
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003  (Issue 1148)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Oxaliplatin (Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil, and others) and leucovorin (LV; Wellcovorin) for patients with metastatic colorectal cancer whose disease has recurred or progressed despite treatment with 5-FU/LV plus irinotecan (Camptosar - Medical Letter 1997; 39:8).
Med Lett Drugs Ther. 2003 Jan 20;45(1148):7-8 |  Show IntroductionHide Introduction

Aripiprazole (Abilify) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003  (Issue 1150)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
Med Lett Drugs Ther. 2003 Feb 17;45(1150):15-6 |  Show IntroductionHide Introduction

Montelukast (Singulair) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Montelukast (Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma (Treatment Guidelines from The Medical Letter 2002; 1:11), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):21-2 |  Show IntroductionHide Introduction